Suchergebnisse - "Wu, Y L"

PubPharm (6)

1

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2018

von Chen, R. | Chen, H. | Jiang, B. | +6

2

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

enthalten in: Revista de oncología | 2017

von Chen, R. | Chen, H. | Jiang, B. | +6

3

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC : data of subgroup analyses from MO19390 (SAiL) study

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2014

von Zhou, C. | Bai, C. | Guan, Z. | +6

4

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

enthalten in: Clinical & translational oncology | 2014

von Zhou, C. | Bai, C. | Guan, Z. | +6

5

Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy

enthalten in: Cancer gene therapy | 2014

von An, S. | Huang, Y. | Chen, Z. | +7

6

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

enthalten in: Revista de oncología | 2013

von Zhou, C. | Bai, C. | Guan, Z. | +6

1
[1]